secwatch.observer — SEC 8-K summary
======================================

Issuer:     C4 Therapeutics, Inc. (CCCC)
CIK:        0001662579
Form:       8-K
Filed at:   2024-12-09T23:59:59+00:00
Accession:  0001628280-24-050349
Event type: other_material
Sentiment:  positive
Materiality: 0.80
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

C4 Therapeutics presents cemsidomide Phase 1 data: 36% ORR in MM, 44% ORR in PTCL at ASH
--------------------------------------------------------------------------------

- In MM with dexamethasone, 36% ORR and 45% CBR at 75 µg QD; no dose reductions due to AEs.
- In NHL monotherapy, 38% ORR across subtypes; in PTCL, 44% ORR and 19% complete metabolic response rate.
- Neutropenia manageable; no discontinuations due to neutropenia; MTD not yet reached.
- Next steps: complete Phase 1 dose escalation, initiate combo trials, engage regulators on path.
- Data support potential best-in-class IKZF1/3 degrader for MM and NHL.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1662579/000162828024050349/0001628280-24-050349-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1662579/000162828024050349/cccc-20241209.htm
  HTML page:      https://secwatch.observer/filing/0001628280-24-050349

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer